PF-07275315 for people with moderate to severe COPD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2/3, randomized, placebo-controlled study gives PF-07275315 or placebo as multiple injections over 24 weeks (phase 2) or 52 weeks (phase 3) and compares outcomes to placebo. Eligible participants have had moderate-to-severe COPD for at least 12 months, a history of two or more moderate/severe exacerbations in the prior year, and are on stable LABA+LAMA+ICS therapy. The trial monitors safety and clinical outcomes over the treatment period to see if the medicine reduces exacerbations or improves lung function and symptoms. Standard exclusion criteria include other significant pulmonary diseases and severe resting hypoxemia or need for continuous high-flow oxygen.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition).
* Spirometry values (post-bronchodilator forced expiratory volume in 1 second \[FEV1\]/forced vital capacity \[FVC\] less than \[\<\] 70 percent (%) and post-bronchodilator FEV1 % predicted \<70%, but greater than equal to 30%).
* Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3 months
* Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening.

Key Exclusion Criteria:

* Significant pulmonary disease other than COPD.
* Requirement for continuous chronic treatment with oxygen at \>4.0 liters / minute by nasal cannula or equivalent.
* Hypoxemia with a resting SpO2 \<88% while breathing ambient air (or on the participant's usual level of oxygen supplementation).
* Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale.

Where it's running

• University of Alabama at Birmingham Lung Health Center
  Birmingham, Alabama, United States Recruiting
• SEC Clinical Research
  Dothan, Alabama, United States Recruiting
• Pulmonary Associates of Mobile, P.C.
  Mobile, Alabama, United States Recruiting
• Pulmonary Associates, PA
  Phoenix, Arizona, United States Recruiting
• IMAX Clinical Trials
  La Palma, California, United States Recruiting
• NewportNativeMD, Inc.
  Newport Beach, California, United States Recruiting

+139 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Marstacimab for mild to moderate hemophilia A or B in people without inhibitors

  This study tests whether weekly injections of marstacimab can reduce bleeding in adolescents and adults with mild to moderate hemophilia A or B who don’t have inhibitors.

  Recruiting Phase 3 Pfizer · Flowood, Mississippi · NCT07923981

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Berobenatide in adults with sleep apnea and obesity who don’t use a PAP machine

  This study tests berobenatide versus placebo in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity who are not using PAP therapy.

  Recruiting at 3 sites Phase 3 Pfizer · Cullman, Alabama and 3 other locations · NCT07881757

• Berobenatide: how it enters the blood after different delivery methods in adults with overweight or obesity

  This study tests a single dose of Berobenatide to see how it behaves in the body when given in different delivery forms to adults with overweight or obesity.

  Recruiting Phase 1 Pfizer · Anaheim, California · NCT07876531

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.